Cambiar Investors LLC Decreases Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Cambiar Investors LLC cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 12.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,050 shares of the medical research company's stock after selling 5,880 shares during the quarter. Cambiar Investors LLC owned approximately 0.08% of Charles River Laboratories International worth $7,393,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRL. Wellington Management Group LLP lifted its stake in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after buying an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Mizuho Securities USA LLC raised its holdings in Charles River Laboratories International by 2,336.4% in the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock valued at $19,081,000 after acquiring an additional 92,895 shares during the last quarter. Premier Fund Managers Ltd raised its holdings in Charles River Laboratories International by 56.3% in the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock valued at $49,573,000 after acquiring an additional 90,000 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after acquiring an additional 85,759 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 0.7 %

Shares of NYSE:CRL traded down $1.10 during mid-day trading on Friday, reaching $152.07. 841,129 shares of the company were exchanged, compared to its average volume of 971,344. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37. The firm's 50-day simple moving average is $176.43 and its 200 day simple moving average is $191.11. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00.

Analyst Ratings Changes

A number of analysts have commented on CRL shares. TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a report on Thursday, November 7th. Finally, Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and a consensus price target of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).